BiVictriX Therapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2019
Net Income	-2.67	-2.55	-2.5	-2.34	-0.43	-0.41	Upgrade
Depreciation & Amortization	0.18	0.17	0.15	0.05	0	-	Upgrade
Asset Writedown & Restructuring Costs	0	0	-	-	-	-	Upgrade
Stock-Based Compensation	0.09	0.07	0.13	0.22	0	0	Upgrade
Other Operating Activities	-0.04	0.05	-0.27	0.53	0.05	-0.02	Upgrade
Change in Accounts Receivable	0.01	0.08	0.06	-0.23	-0.04	0.02	Upgrade
Change in Accounts Payable	0.15	0.21	0.03	-0.02	0.24	0.05	Upgrade
Operating Cash Flow	-2.27	-1.96	-2.4	-1.79	-0.17	-0.36	Upgrade
Capital Expenditures	0.15	-0.01	-0.39	-0.05	-0.06	-	Upgrade
Sale of Property, Plant & Equipment	-	-	0.01	-	-	-	Upgrade
Other Investing Activities	0.04	0.02	-	-	-	-	Upgrade
Investing Cash Flow	0.19	0.02	-0.38	-0.05	-0.06	-	Upgrade
Long-Term Debt Issued	-	-	-	-	0.8	-	Upgrade
Long-Term Debt Repaid	-	-0.12	-	-0.03	-	-	Upgrade
Net Debt Issued (Repaid)	-0.18	-0.12	-	-0.03	0.8	-	Upgrade
Issuance of Common Stock	2.13	2.13	-	7.5	0.18	0.29	Upgrade
Other Financing Activities	-0.08	-0.08	-	-0.44	-0.02	-0.01	Upgrade
Financing Cash Flow	1.87	1.94	-	7.03	0.96	0.28	Upgrade
Net Cash Flow	-0.22	-0.01	-2.78	5.2	0.73	-0.08	Upgrade
Free Cash Flow	-2.12	-1.97	-2.79	-1.83	-0.23	-0.36	Upgrade
Free Cash Flow Per Share	-0.03	-0.03	-0.04	-0.05	-0.01	-3.73	Upgrade
Cash Income Tax Paid	-	-0.52	-0.21	-0.08	-0.12	-0.1	Upgrade
Levered Free Cash Flow	-1.35	-1.31	-2.19	-1.47	-0.16	-0.28	Upgrade
Unlevered Free Cash Flow	-1.35	-1.31	-2.19	-1.07	-0.15	-0.28	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.